4.5 Article

Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS

期刊

NEUROBIOLOGY OF AGING
卷 34, 期 9, 页码 -

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2013.04.004

关键词

Frontotemporal lobar degeneration; FUS; FET proteins; PRMT1; PRMT3; PRMT8; Protein N-arginine methyltransferase

资金

  1. Mayo Benefactor
  2. Mayo Foundation
  3. National Institute of Health [P50 AG016574, R01 NS065782, R01 AG026251, R01 AG037491, P50 AG023501]
  4. The Consortium for Frontotemporal Dementia Research
  5. Swiss National Science Foundation [31003A-132864]
  6. Canadian Institutes of Health Research [74580]
  7. Pacific Alzheimer's Research Foundation [C06-01]
  8. Sydney Brain Bank
  9. National Health and Medical Research Council of Australia
  10. The University of New South Wales
  11. Neuroscience Research Australia
  12. Swiss National Science Foundation (SNF) [31003A_132864] Funding Source: Swiss National Science Foundation (SNF)

向作者/读者索取更多资源

The nuclear protein fused in sarcoma (FUS) is found in cytoplasmic inclusions in a subset of patients with the neurodegenerative disorder frontotemporal lobar degeneration (FTLD-FUS). FUS contains a methylated arginine-glycine-glycine domain that is required for transport into the nucleus. Recent findings have shown that this domain is hypomethylated in patients with FTLD-FUS. To determine whether the cause of hypomethylation is the result of mutations in protein N-arginine methyltransferases (PRMTs), we selected 3 candidate genes (PRMT1, PRMT3, and PRMT8) and performed complete sequencing analysis and real-time polymerase chain reaction mRNA expression analysis in 20 FTLD-FUS cases. No mutations or statistically significant changes in expression were observed in our patient samples, suggesting that defects in PRMTs are not the cause of FTLD-FUS. (C) 2013 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据